Skip to content
Clinical Trials – home

Vivamed Clinic S.R.L.

Research site

Romania Strada Rezervelor Nr. 67 L2 T76/2 P7 Etajul 1, Chiajna, 077042 Rosu, Romania

  • Atrial fibrillation
  • Adult patients

About Specializations

Vivamed Clinic S.R.L. in Rosu, Romania specialises in clinical trials of conditions such as Atrial fibrillation, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research at Vivamed Clinic

The cardiology department of Vivamed Clinic S.R.L. is dedicated to advancing cardiovascular diseases research, with a primary focus on atrial fibrillation. Ongoing studies aim to lower the incidence of stroke and systemic embolism while improving safety regarding bleeding events.

  • Evaluation of novel anticoagulant agents for stroke prevention
  • Safety profiling of bleeding risk in patients unsuitable for oral anticoagulation
  • Comparative effectiveness versus standard therapy such as apixaban
  • Investigation of combined therapeutic strategies to reduce systemic embolism

The trials are conducted under a European regulatory framework, providing participants with access to innovative treatments and rigorous safety monitoring.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Strada Rezervelor Nr. 67 L2 T76/2 P7 Etajul 1, Chiajna077042 RosuRomania
Recruiting now
no trials
Conditions studied
1

More sites in RosuRomania

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.